Diagnosis of Alzheimer’s disease

The current challenges

Until recently, the diagnosis of AD was based on clinical and neuropsychological evaluations performed by a neurologist. However, new guidelines for AD diagnosis published in 2011 encourage the use of biomarkers, especially for the preclinical (asymptomatic) and early disease stages.

As a consequence, enormous research effort in recent years has focused on the development and validation of biomarkers that can predict AD or detect the earliest stages of the disease. Biomarker-based approaches currently used for AD diagnosis include cerebrospinal fluid analysis to detect specific proteins (Aβ and Tau) and imaging techniques such as MRI and PET/SPECT to assess brain functionality and/or detect morphological alterations and amyloid peptide accumulation in the brain.

Although the predictive accuracy of these biomarkers for AD in research settings is higher than that of classical clinical and neuropsychological evaluations, their validity for routine use in clinical settings remains the subject of intense debate within the medical community.

Among other drawbacks, technical and logistical issues hamper the widespread application of these biomarkers in general clinical practice:

  • They are expensive
  • It’s required trained personnel to interpret the results
  • They are not yet fully standardized
  • In some cases involve invasive procedures

The development of biomarkers that could be measured directly in blood would greatly facilitate the implementation and use of biomarkers for clinical diagnosis.

Diagnosis of Alzheimer’s disease

To fulfill this unmet need, Biocross has developed a series of blood-based diagnostic kits for the identification of AD patients throughout all stages of the disease spectrum, i.e., from the detection of at-risk individuals to the diagnosis of AD, even at the earliest stages.

To fulfill this unmet need, Biocross has developed a series of blood-based diagnostic kits for the identification of AD patients throughout all stages of the disease spectrum, i.e., from the detection of at-risk individuals to the diagnosis of AD, even at the earliest stages.

Biocross’ kits are simple, provide rapid results, and are designed for easy incorporation into
the clinical routine of hospitals.

Biocross’ kits are simple, provide rapid results, and are designed for easy incorporation into
the clinical routine of hospitals.

If you have any questions or comments,  we will be pleased to attend you

If you have any questions or comments,  
we will be pleased to attend you

Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain

+34 983 54 98 96